Two professionals from the Laboratory will travel to the Japanese capital to support the anti-doping work that will take place during the Olympic Games, which begin on July 23. The Hospital del Mar Institute for Medical Research (IMIM) will once again be Olympic. Two of the Anti-Doping Laboratory of Catalonia professionals at IMIM will work at the Olympic Games Laboratory in Tokyo, which starts this July 23. Sergi Coll and Lídia Requena will travel to Tokyo to work there until August 10. Sergi Coll specializes in detecting anabolic steroids, and Lídia Requena specializes in detecting hormones (erythropoietin, growth hormone ...) and blood transfusions.
Combining chemotherapy with a BRAF oncogene inhibitor proves effective at treating this disease. The study, published in the journal Oncogene, was led by researchers from the Hospital del Mar Medical Research Institute, Hospital del Mar and CIBERONC. This alternative paves the way towards a new approach for patients affected by this type of tumor, which has no cure in the most advanced stages or cases of relapse.
Més informació "A new approach to metastatic melanoma discovered"
Dr Joan Albanell, head of the Medical Oncology Department at Hospital del Mar and director of the Cancer Research Programme at the Hospital del Mar Medical Research Institute, is one of the authors of the first article to come out of this study, in which more than sixty hospitals from eleven European countries are taking part. The work, published in the prestigious journal Cancer Discovery, is an important step in understanding the molecular changes that lead to metastasis in breast cancer.
The IMIM has obtained nearly 3.4 million euros in financing from this fund, 12% more than in the 2019 call for proposals, the most recent prior to the pandemic. 60% of the proposals submitted were approved, a record number in the history of the institution.
22/06/2021 - Press release
6.4% of the European population suffers from depression, according to a study published in The Lancet Public Health. The work was led by researchers from King's College London, the Hospital del Mar Medical Research Institute (IMIM), the Parc de Recerca Sant Joan de Déu-Institut de Recerca Sant Joan de Déu, the Institute of Biomedicine at the University of León (IBIOMED), and the CIBER on Epidemiology and Public Health (CIBERESP). This figure is higher than that estimated by the World Health Organisation (WHO), which calculated the prevalence of this pathology in the European region at 4.2%. Depression is considered to be one of the leading causes of disability around the world, increasing the risk of premature death, decreasing quality of life and being a heavy burden on health systems. In fact, it is estimated that it may affect more than 300 million people worldwide.
Més informació "More than 6% of Europeans suffer from depression"
21/06/2021 - Press release
As a result of the collaboration between research centres in Italy and Spain, the PEGASUS study has been launched with the aim of demonstrating that, thanks to the liquid biopsy guidance tool, it is possible to increase the precision of post-surgical treatment for colon cancer patients. The Vall d'Hebron Institute of Oncology (VHIO), part of the Vall d'Hebron Campus, and the Hospital del Mar Medical Research Institute (IMIM), both in Barcelona; and the INCLIVA Health Research Institute at Hospital Clínico in Valencia, are the three Spanish centres taking part in this project. The study was instigated by Dr. Silvia Marsoni, from the FIRC Institute of Molecular Oncology (IFOM) in Milan, and is supported by the AIRC Foundation within the 5x1000 programme, which is coordinated by Prof. Alberto Bardelli of the University of Turin and the Institute of Candiolo FPO-IRCCS.
16/06/2021 - General information
On June 15th and 16th, the STOPSTORM consortium coordinated by the UMC Utrecht with the IMIM and Hospital del Mar's participation, met virtually to discuss early project progress. The project, which officially started on May 1st, will begin researching the use of radiotherapy in treating cardiac arrhythmias. Patients who suffer from ventricular tachycardia (fibrillation of the ventricles) are often treated with medication and/or implantation of an ICD, a defibrillator that corrects a rapid heart rate with an electric shock. In cases of persistent arrhythmias that do not respond adequately to regular therapy, patients may undergo invasive catheter ablation. The aim of the consortium, consisting of 31 partners across 8 European countries, is to investigate the option of radiotherapy-ablation for the 30%-50% of patients whose symptoms persist after catheter ablation. The treatment, which is also used in lung oncology, consists of a high dose of radiation administered in a single session.
Més informació "Launch of European research into radiotherapy for cardiac arrhythmias"
15/06/2021 - General information
This year's edition of the charitable initiative, promoted by the Catalan Media Corporation (Corporació Catalana de Mitjans Audiovisuals), raised nearly fourteen million euros to fund research into COVID-19. It was a very special edition that selected two projects led by researchers from Hospital del Mar and the Hospital del Mar Medical Research Institute, as well as a third, joint project, from among the 229 proposals submitted for funding. The Scientific Committee of La Marató de TV3 has decided to fund three research projects on COVID-19 that involve Hospital del Mar and the Hospital del Mar Medical Research Institute. The official announcement was made on 11 June, in a special programme of Al Cotxe presented by Eloi Vila. Two of the studies are led by researchers from the IMIM and Hospital del Mar, while a third is being run jointly with other centres. This latest edition of La Marató raised almost fourteen million euros.
Més informació "Three IMIM and Hospital del Mar projects funded by the 2021 La Marató de TV3"
01/06/2021 - General information
The Jury of the Àngel Prize for Occupational Medicine 2021 has awarded the Prize convened by the Catalan Association of Occupational Health to Dr. Consol Serra Pujadas, in recognition of her dedication to defending health of working people. Consol Serra is the coordinator of the University Pompeu Fabra (UPF) and Hospital del Mar Medical Research Institute (IMIM) Center for research in Occupational Health, Head of the Occupational Health Service of the PSMar and Head of Studies of the "Mateu Orfila-UPF" Occupational Medicine Teaching Unit. The award ceremony will take place on June 15, during the General Assembly of members of the Catalan Association of Occupational Health
Més informació "Consol Serra Angel Award for Occupational Medicine 2021"
19/05/2021 - Press release
Liquid biopsy can predict which patients with localised rectal cancer are likely to relapse, even after initial chemotherapy and radiotherapy treatment, and prior to surgery. This is supported by a study led by doctors and researchers from the Medical Oncology and Pathology Departments at Hospital del Mar, as well as the Hospital de Mar Medical Research Institute (IMIM) and the CIBER in cancer (CIBERONC), which has been published in the American Association for Cancer Research journal, Clinical Cancer Research. The study analysed samples from 72 patients from twenty hospitals in Spain, taken as part of the GEMCAD1402 clinical trial conducted by the Spanish Multidisciplinary Group on Digestive Cancer.
Més informació "Liquid biopsy can predict relapse in patients with locally advanced rectal cancer"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact